Polaryx Therapeutics, Inc. Common Stock (PLYX) — Working Capital to Net Assets Ratio
Polaryx Therapeutics, Inc. Common Stock (PLYX) has a Working Capital to Net Assets ratio of 100.0% as of June 2026. Working capital of $10.94 Million (current assets of $11.81 Million minus current liabilities of $873.00K) is measured against net assets of $10.94 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Polaryx Therapeutics, Inc. Common Stock Working Capital to Net Assets (2023–2025)
This chart shows how Polaryx Therapeutics, Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 3 annual periods from 2023 to 2025. As of June 2026, the ratio stands at 100.0%, reflecting working capital of $10.94 Million against net assets of $10.94 Million USD. For the complete balance sheet picture, see Polaryx Therapeutics, Inc. Common Stock balance sheet assets.
Annual Working Capital to Net Assets for Polaryx Therapeutics, Inc. Common Stock (2023–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Polaryx Therapeutics, Inc. Common Stock from 2023 to 2025, covering 3 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read total liabilities of Polaryx Therapeutics, Inc. Common Stock for a breakdown of total debt and financial obligations.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 100.0% | $4.57 Million | $4.57 Million | $5.17 Million | $605.00K | ▲ +0.0 pp |
| 2024 | 100.0% | $4.71 Million | $4.71 Million | $5.00 Million | $289.00K | ▲ +0.0 pp |
| 2023 | 100.0% | $1.28 Million | $1.28 Million | $2.31 Million | $1.04 Million | — |